Proximal Ventures Raises $27.5 Million to Back AI-Powered Drug Discovery Startups

Proximal Ventures disclosed that its first fund has closed, amassing $27.5 million earmarked for investments in early‑stage firms leveraging artificial intelligence to speed up pharmaceutical research and development.

Sahir Raoof heads the fund; he formerly oversaw investments at SignalFire, a venture firm centered on technology. His track record in identifying fast‑growing tech ventures shapes the firm’s approach to supporting founders who combine machine‑learning methods with biology to compress the drug‑discovery timeline.

In recent years, AI‑driven drug development has become a prime target for investment, driven by breakthroughs in computational chemistry, protein‑folding prediction and massive data analytics that aim to cut the expense and uncertainty of launching new medicines. Proximal Ventures seeks to occupy this space by offering both funding and sector‑specific expertise to guide founders through the regulatory and scientific challenges particular to biotech.

Analysts point out that the debut fund’s $27.5 million size signals a blend of prudence and hope. Though smaller than many established biotech funds, the amount matches the early‑stage profile of numerous AI‑based drug platforms, which typically need seed‑stage capital to validate core algorithms prior to entering expensive pre‑clinical phases.

Raoof stressed that the firm will focus on startups showing a definitive route to marry AI models with experimental verification. “The most attractive prospects are those where computational insight directly guides lab work, establishing a feedback loop that can vastly accelerate candidate selection,” he remarked during a briefing.

Going forward, Proximal Ventures intends to allocate its funds over the next 12 to 18 months, aiming for a varied portfolio covering therapeutic fields like oncology, rare diseases and infectious diseases. The firm’s debut contributes to an expanding network of investors wagering on AI to transform drug discovery, and its performance may reflect wider confidence in the melding of data science with pharmaceutical innovation.